Therefore, the efficacy of an anti-NogoA antibody (ozanezumab) to slow down ALS progression was tested but no difference in disease progression (ALSFRS-R) or in survival was observed [149]. Here, RTN4 is linked to amyotrophic lateral sclerosis.